Severe Eosinophilic Asthma Clinical Trial
Official title:
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.
Phase III clinical trials demonstrated that benralizumab treatment results in a significant decrease in exacerbations and a significant increase in lung function and quality of life in patients with severe eosinophilic asthma. However, the precise underlying mechanisms leading to this clinical benefit of benralizumab treatment are not completely understood. Dendritic cells are key regulators of the adaptive and innate immune system. There is evidence that eosinophils have a direct influence on the function of dendritic cells. In addition, there are multiple indirect interactions between eosinophils and dendritic cells in asthma. However, there is currently no information on the impact of benralizumab treatment and a complete removal of circulating eosinophils on the number and phenotype of human dendritic cells. Benralizumab is chosen for this study because it is the only anti-IL-5 biologic which results in a complete removal of eosinophils from peripheral blood. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
| Completed |
NCT02560610 -
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
|
Phase 2 | |
| Recruiting |
NCT06069310 -
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
|
||
| Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
| Completed |
NCT05180357 -
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
|
||
| Active, not recruiting |
NCT03833141 -
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
|
||
| Completed |
NCT05271526 -
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
|
||
| Not yet recruiting |
NCT06302959 -
Clock Proteins as Prognostic Markers
|
||
| Recruiting |
NCT05440656 -
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
|
||
| Completed |
NCT04159519 -
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
|
Phase 4 | |
| Completed |
NCT03907137 -
Real World Study With Benralizumab in Severe Asthma in Switzerland
|
||
| Active, not recruiting |
NCT04084613 -
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
|
||
| Completed |
NCT04126499 -
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
|
||
| Recruiting |
NCT03739320 -
A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma
|